Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial-Reference-Cited by-同舟云学术

Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

Published:2015-04 Issue:4 Volume:22 Page:361-373
ISSN:1556-6811
Container-title:Clinical and Vaccine Immunology
language:en
Short-container-title:Clin Vaccine Immunol

Author:

Apter Dan¹,Wheeler Cosette M.²,Paavonen Jorma³,Castellsagué Xavier⁴,Garland Suzanne M.⁵,Skinner S. Rachel⁶,Naud Paulo⁷,Salmerón Jorge⁸,Chow Song-Nan⁹,Kitchener Henry C.¹⁰,Teixeira Julio C.¹¹,Jaisamrarn Unnop¹²,Limson Genara¹³,Szarewski Anne¹⁴,Romanowski Barbara¹⁵,Aoki Fred Y.¹⁶,Schwarz Tino F.¹⁷,Poppe Willy A. J.¹⁸,Bosch F. Xavier¹⁹,Mindel Adrian²⁰,de Sutter Philippe²¹,Hardt Karin²²,Zahaf Toufik²²,Descamps Dominique²²,Struyf Frank²²,Lehtinen Matti²³,Dubin Gary²⁴

Affiliation:

1. Family Federation of Finland, Sexual Health Clinic, Helsinki, Finland

2. Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA

3. Department of Obstetrics and Gynaecology, University of Helsinki, Helsinki, Finland

4. Cancer Epidemiology Research Program, Institut Català d'Oncologia (ICO), IDIBELL, Biomedical Research Centre Network for Epidemiology and Public Health (CIBER-ESP), L'Hospitalet de Llobregat, Catalonia, Spain

5. Microbiology and Infectious Diseases Department, Royal Women's Hospital and Department of Obstetrics and Gynaecology, University of Melbourne, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia

6. Vaccine Trials Group, Telethon Institute for Child Health Research, Perth, Western Australia, and Sydney University Discipline of Paediatrics and Child Health, Children's Hospital at Westmead, Sydney, New South Wales, Australia

7. University Federal of Rio Grande do Sul, Hospital de Clínica de Porto Alegre, Porto Alegre, Brazil

8. Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Morelos, Mexico

9. Department of Obstetrics and Gynecology, College of Medicine and the Hospital, National Taiwan University, Taipei, Taiwan

10. Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, United Kingdom

11. University of Campinas, Campinas, Brazil

12. Chulalongkorn University, Department of Obstetrics and Gynaecology, Faculty of Medicine, Bangkok, Thailand

13. University of the Philippines, College of Medicine, Philippine General Hospital, Makati Medical Centre, Makati City, Philippines

14. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

15. University of Alberta, Edmonton, Alberta, Canada

16. University of Manitoba, Winnipeg, Manitoba, Canada

17. Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Academic Teaching Hospital of the University of Wuerzburg, Wuerzburg, Germany

18. Department of Gynaecology, University Hospital KU Leuven Gasthuisberg, Leuven, Belgium

19. Cancer Epidemiology Research Program, Institut Català d'Oncologia (ICO), IDIBELL, Network on Cooperative Cancer Research (RTICC), L'Hospitalet de Llobregat, Catalonia, Spain

20. Centre for AIDS Programme of Research in South Africa, Durban, South Africa

21. Afdelingshoofd Gynaecologie-Oncologie, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium

22. GSK Vaccines, Wavre, Belgium

23. University of Tampere, School of Public Health, Tampere, Finland

24. GSK Vaccines, King of Prussia, Pennsylvania, USA

Abstract

ABSTRACT We report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 ((HPV-16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from the PApilloma TRIal against Cancer In young Adults (PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one vaccine dose (vaccine, n = 9,319; control, n = 9,325) at months 0, 1, and/or 6. The TVC-naive (vaccine, n = 5,822; control, n = 5,819) had no evidence of high-risk HPV infection at baseline, approximating adolescent girls targeted by most HPV vaccination programs. Mean follow-up was approximately 39 months after the first vaccine dose in each cohort. At baseline, 26% of women in the TVC had evidence of past and/or current HPV-16/18 infection. HPV-16 and HPV-18 antibody titers postvaccination tended to be higher among 15- to 17-year-olds than among 18- to 25-year-olds. In the TVC, vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or greater (CIN1+), CIN2+, and CIN3+ associated with HPV-16/18 was 55.5% (96.1% confidence interval [CI], 43.2, 65.3), 52.8% (37.5, 64.7), and 33.6% (−1.1, 56.9). VE against CIN1+, CIN2+, and CIN3+ irrespective of HPV DNA was 21.7% (10.7, 31.4), 30.4% (16.4, 42.1), and 33.4% (9.1, 51.5) and was consistently significant only in 15- to 17-year-old women (27.4% [10.8, 40.9], 41.8% [22.3, 56.7], and 55.8% [19.2, 76.9]). In the TVC-naive, VE against CIN1+, CIN2+, and CIN3+ associated with HPV-16/18 was 96.5% (89.0, 99.4), 98.4% (90.4, 100), and 100% (64.7, 100), and irrespective of HPV DNA it was 50.1% (35.9, 61.4), 70.2% (54.7, 80.9), and 87.0% (54.9, 97.7). VE against 12-month persistent infection with HPV-16/18 was 89.9% (84.0, 94.0), and that against HPV-31/33/45/51 was 49.0% (34.7, 60.3). In conclusion, vaccinating adolescents before sexual debut has a substantial impact on the overall incidence of high-grade cervical abnormalities, and catch-up vaccination up to 18 years of age is most likely effective. (This study has been registered at ClinicalTrials.gov under registration no. NCT001226810.)

Publisher

American Society for Microbiology

Subject

Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy

Link

https://journals.asm.org/doi/pdf/10.1128/CVI.00591-14

Reference44 articles.

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. 2012. GLOBOCAN v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr. Accessed 1 September 2014.

2. The causal relation between human papillomavirus and cervical cancer

3. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

4. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials

5. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Human Papillomavirus Vaccination Challenges and Strategies to Enhance Uptake;Vaccines;2024-07-06

2. Prospects for Comprehensive Screening and Treatment of Cervical Cancer;Creative surgery and oncology;2024-04-18

3. Cost-effectiveness of nonavalent HPV vaccination in the Netherlands;Expert Review of Vaccines;2024-03

4. Lives Saved Through Increasing Adherence to Follow-Up After Abnormal Cervical Cancer Screening Results;O&G Open;2024-03

5. A Review of Human Papillomavirus Vaccination and Associated Ethical Concerns;Infection & Chemotherapy;2024